Your session is about to expire
← Back to Search
Itacitinib for Graft-versus-Host Disease (GVHD Trial)
GVHD Trial Summary
This trial is designed to assess the safety and effectiveness of a combination of two drugs to treat patients with a specific kind of graft versus host disease that has not responded to steroids. The secondary objectives are to estimate response rates, time to response, duration of response, and progression-free survival, among other things.
- Steroid Refractory Graft-versus-Host Disease
- Graft-versus-Host Disease
GVHD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGVHD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 439 Patients • NCT03139604GVHD Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the qualifications for participating in this medical research?
"Inclusion into this trial requires that patients have the specified disease and be within a certain age range (18-99). Currently, around 24 volunteers are being sought."
Are participants currently being sought for this medical research?
"Confirmed. According to the clinicaltrials.gov website, this medical trial is currently accepting applications from participants; it was initially posted on January 20th 2020 and updated most recently on April 28th 2022. A total of 24 individuals are needed at 2 sites for enrollment in the study."
What precedent has been established with other experiments concerning Itacitinib?
"Currently, there are 93 trials being conducted on Itacitinib. Of those studies, 9 have reached Phase 3 status. Most of the locations conducting clinical research with this medication are in Poznan and New york; however, a total of 1850 sites around the world are participating in these trials."
Are elderly persons excluded from this investigation?
"The requirements for this trial state that applicants must be within the 18-99 year old age range. There are 74 trials open to those underage and 231 specifically targeting seniors above 65 years of age."
What is the intended outcome of this research project?
"Incyte Corporation, the clinical trial sponsor, reported that the primary evaluation metric is Access Safety and Tolerability. This measurement will be taken 28 to 35 days after End-of-Treatment (EOT) or last dose of study drug. Secondary outcomes include Incidence of Infections, Proportion of Patients Discontinuing Steroids, and Incidence of Disease Relapse."
What is the magnitude of participation in this medical research?
"Affirmative. Clinicaltrials.gov displays that this investigation, which was initially published on January 20th 2020, is currently enrolling participants. 24 individuals must be sourced from two distinct medical centers."
Has the FDA approved Itacitinib for use in clinical practice?
"As the trial is still in its first phase, safety and efficacy data remains relatively minimal; thus, this drug was given a rating of 1."
Share this study with friends
Copy Link
Messenger